title: [Progress on study of treatment of age-related macular degeneration by pigment epithelial-derived factor].
abstract: Age-related macular degeneration (AMD) is a common cause of blindness in elderly population. Exploration of effective treatment of AMD has important significance. Pigment epithelial-derived factor (PEDF) is the most powerful endogenous inhibitor of angiogenesis. Increasing evidences, including results of phase I clinical trial, indicated that PEDF could significantly inhibit the development of choroidal neovascularization, which is the characteristic of wet AMD. Therefore, PEDF is one of the most potential therapeutic agents for AMD treatment.
authors.affiliation: Department of Ophthalmology, Eye Institute of Chinese PLA, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.
authors.forename: Hui-yuan
authors.initials: HY
authors.lastname: Hou
authors.forename: Yu-sheng
authors.initials: YS
authors.lastname: Wang
mesh_terms: D020256:Choroidal Neovascularization; D005136:Eye Proteins / Q000627:therapeutic use*; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy* / Q000473:pathology; D009414:Nerve Growth Factors / Q000627:therapeutic use*; D015843:Serpins / Q000627:therapeutic use*; D042461:Vascular Endothelial Growth Factor A / Q000627:therapeutic use*; D000099174:Pigment Epithelium-Derived Factor
chemical_list: D005136:Eye Proteins; D009414:Nerve Growth Factors; D015843:Serpins; D042461:Vascular Endothelial Growth Factor A; D000099174:Pigment Epithelium-Derived Factor